The American Journal of Managed Care7d
FDA Approves Celltrion’s Tocilizumab-anoh, Biosimilar to Actemra
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...
Healio7d
FDA approves third Actemra biosimilar; second available in intravenous, subcutaneous forms
The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.
Pharmabiz6d
Celltrion’s Avtozma, a biosimilar to Actemra receives US FDA approval to treat RA, GCA, pJIA, sJIA and Covid-19
Jersey City, New Jersey Saturday, February 1, 2025, 16:00 Hrs [IST] ...
Medscape5d
Immunotherapeutic Implication of IL-6 Blockade
Tocilizumab has Been Approved for the Treatment of Rheumatoid Arthritis, Systemic Juvenile Idiopathic Arthritis & Castleman's Disease Tocilizumab was developed in response to the expectation that ...
Medscape5d
Tocilizumab: The First Interleukin-6-Receptor Inhibitor
Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, and role of tocilizumab in rheumatoid arthritis (RA) are reviewed. Summary: Tocilizumab is a novel monoclonal antibody that ...
Monthly Prescribing Reference7d
FDA Approves Tocilizumab Biosimilar Avtozma
Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity with Actemra. The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab ...
PipelineReview.com7d
U.S. FDA approves Celltrion’s AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA®
JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...